Products
& platforms

Adocia mission is to develop innovative formulations of approved peptides and novel cell therapy approaches for the treatment of diabetes and obesity. 

Contact us Arrow right

Pipeline

Over the years, Adocia has built a diversified pipeline of specialty products for the treatment of diabetes and obesity.
The products development stage ranges from preclinical proof of concept to Phase 3 clinical trials.

Diabetes Ultra-Rapid Insulin

BioChaperone®
Lispro

PreclinicPhase 1Phase 2Phase 3
Phase 3 in China ongoing
Phase 3 in USA / Europe ready to start upon partnership signature

Partnering: Licensed to Tonghua Dongbao for China and other Asian territories. Available for other territories.

Product description: BioChaperone® Lispro (BC Lispro) is a novel ultra-rapid prandial insulin formulation containing insulin lispro and Adocia proprietary technology platform BioChaperone®. The BioChaperone® excipient ensures a faster absorption of insulin post injection and enables a more effective management of blood glucose levels.

Platform: BioChaperone®

Diabetes Insulins Combination,
Long acting + Rapid acting

BioChaperone® Combo

PreclinicPhase 1Phase 2Phase 3
Phase 1 completed - preparation of a direct to Phase 3 approach

Partnering: Licensed to Tonghua Dongbao for China and other Asian territories. Available for other territories.

Product description: BioChaperone® Combo(BC Combo) is a fixed combination of two gold standard insulins: long-acting insulin glargine and rapid-acting insulin lispro. BC Combo is a safer alternative to premixed insulin for treatment intensification in people with type 2 diabetes with a reduction of the level of postprandial hyperglycemia and the risk of late hypoglycemia.

Platform: BioChaperone®

Diabetes Immunoprotective Scaffold for Cell Therapy

AdoShell®
Islets

PreclinicPhase 1Phase 2Phase 3
2023 First in Human preparation with islets of Langerhans

Partnering: Available for partnering

Product description: AdoShell® Islets is a hydrogel-based implant containing islets of Langerhans for cell therapy against type 1 diabetes.
It improves significantly the current transplantation protocols by removing the immunosuppressive treatment and making the implanted islets retrievable.

Platform: AdoShell®

Diabetes & Obesity Droits exclusifs de négociation d’un partenariat mondial accordés à Sanofi sur les combinaisons insulin-pramlintide

M1Pram

PreclinicPhase 1Phase 2Phase 3
Exclusive rights on all insulin-pramlintide combination granted to Sanofi to negotiate a global partnership

Partnering: Sanofi

Product description: M1Pram is a ready-to-use co-formulation of pramlintide (an amylin analog) and M1 (a mealtime insulin analog).
Adocia has developed M1Pram to enable patients affected by both diabetes and overweight or obesity to address weight management and glycemic control as co-primary targets of care.

Diabetes & Obesity Insulin-pramlintide combination

BioChaperone® LisPram

PreclinicPhase 1Phase 2Phase 3
Exclusive rights on all insulin-pramlintide combination granted to Sanofi to negotiate a global partnership

Partnering: Sanofi

Product description: BioChaperone® LisPram is a ready-to-use co-formulation of pramlintide (an amylin analog) and lispro (gold standard mealtime insulin analog). It is designed to be administered via insulin pump, in which it differs from M1Pram. BioChaperone® LisPram aims to maintain a good glycemic control, while triggering significant weight loss.

Platform: BioChaperone®

Diabetes & Obesity Oral form of GLP-1 semaglutide

AdOral®
Sema

PreclinicPhase 1Phase 2Phase 3
2024 First in Human upon partnership condition

Partnering: Available for partnering

Product description: AdOral® Sema is an orally administered glucagon-like peptide 1 (GLP1) receptor agonist: semaglutide. Adocia has applied its AdOral® technology to switch the active molecule from an injectable to an oral form.

Platform: AdOral®

Obesity Long-Acting Injectable

AdoGel® Sema

PreclinicPhase 1Phase 2Phase 3
2023 Preclinical POC

Partnering: Available for partnering

Product description: AdoGel® Sema is a ready-to-use injectable hydrogel for long-acting drug delivery of semaglutide. Preclinical proof of concept is underway. The key differentiating attribute lies in its controlled release mechanism allowed by the AdoGel ® platform, characterized by nearly zero-order kinetics with no initial burst, ensuring steady release of the semaglutide into the bloodstream.

Platform: AdoGel®